A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Status:
Completed
Trial end date:
2019-11-14
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the
safety and efficacy of 3 dose levels of oral CR845 compared to placebo in reducing the
intensity of itch in chronic kidney disease (CKD) patients with moderate-to-severe pruritus.
This study will consist of a Screening Period, a 7-day Run-in Period, a 12 week Treatment
Period, and a Follow-up Visit (approximately 7 days after the last dose of study drug).